Sponsored Seminars

* Luncheon seminar reservation is only available for English Seminar.

Luncheon Seminar

Luncheon Seminar 1

Non-invasive FFRCT - Considering appropriate non-invasive cardiac testing -

Co-sponsor:

HeartFlow Japan G.K.

Luncheon Seminar 2

How ivabradine works in the treatment of heart failure with reduced ejection fraction?

Co-sponsor:

ONO PHARMACEUTICAL CO., LTD.

Luncheon Seminar 3

Cardiovascular Prevention in Middle Income Countries of Asia

Co-organizer:

Japan Cardiovascular Association (JCVA)

Luncheon Seminar 4

Stroke prevention in atrial fibrillation: Perspectives from Asia

Co-sponsor:

Bristol-Myers Squibb / Pfizer Japan Inc.

Luncheon Seminar 5

The Clinical Implication of Intensive Lipid lower treatment for ACS

Co-sponsor:

Sanofi K.K.

Luncheon Seminar 6

Decongestion therapy in acute heart failure : based on real world

Co-sponsor:

Otsuka Pharmaceutical Co.,Ltd.

Luncheon Seminar 72

APSC Consensus Statement Lunch Symposium 1

Co-sponsor:

Asian Pacific Society of Cardiology Congress

Luncheon Seminar 73

The Forefront of ICT Utilization on the Field of Cardiology in Japan

Co-sponsor:

MID, Co.,Ltd.

Luncheon Seminar 7

Consensus of congestion treatment for heart failure considering cardio-renal syndrome

Co-sponsor:

Otsuka Pharmaceutical Co.,Ltd.

Luncheon Seminar 8

Plaque Imaging for Clinical Practice

Co-sponsor:

Kowa Company, Ltd.

Luncheon Seminar 9

Biophysics of RF Ablation: New Ablation Modalities to Optimize RF Energy Delivery in AF Ablation

Co-sponsor:

Johnson & Johnson K.K. Medical Company

Luncheon Seminar 10

Mineralocorticoid receptor-associated hypertension and its organ damage

Co-sponsor:

Daiichi Sankyo Co.,Ltd.

Luncheon Seminar 11

The Significance of BNP-test for the Imminent Upsurge of Elderly Heart Failure - Responding to the Establishment of Basic Control Act -

Co-sponsor:

SHIONOGI & CO., LTD. / Tosoh Corporation/LSI Medience Corporation/SEKISUI MEDICAL CO.,LTD. / FUJIREBIO INC.

Luncheon Seminar 12

Acute Kidney Injury in Medical Cardiac Intensive Care Units：Clinical Significance of Measurements of Urinary L-FABP Concentration

Co-sponsor:

CMIC HOLDINGS Co., Ltd. / SEKISUI MEDICAL CO., LTD.

Luncheon Seminar 13

Anticoagulation for Venous Thromboembolism 2020:-Recent progress, Remaining Challenges-

Co-sponsor:

Bayer Yakuhin, Ltd.

Luncheon Seminar 14

APSC Consensus Statement Lunch Symposium 2
Use of High Sensitivity Troponin Assays

Co-sponsor:

Asian Pacific Society of Cardiology Congress

Luncheon Seminar 15

Treatment Strategy for Pulmonary Artery Hypertension
～Effects and Limitations of Oral Medical Treatment～

Co-sponsor:

NIPPON SHINYAKU CO., LTD. / Actelion Pharmaceuticals Japan Ltd.

Luncheon Seminar 16

The up-to-date diagnosis of syncope and arrhythmia treatment from the viewpoint of guidelines

Co-sponsor:

Medtronic Japan Co., Ltd.

Luncheon Seminar 17

New Evidence of Comprehensive Cardiovascular Risk Management

Co-sponsor:

Fukuda Denshi Co., Ltd.

Luncheon Seminar 18

How could we manage residual risk of coronary heart diseases?

Co-sponsor:

Takeda Pharmaceutical Company Limited

Luncheon Seminar 19

For Safe and Speedy Procedure of Atrial Fibrillation

Co-sponsor:

Abbott Medical Japan LLC

Luncheon Seminar 20

Guideline of Diabetes Therapy for Cardiovascular Prevention ～ from JDS, JCS Joint Statement～

Co-sponsor:

MSD K.K. / Astellas Pharma Inc. / Kotobuki pharmaceutical Co., Ltd.

Luncheon Seminar 21

Cancer Associated Thrombosis

Co-sponsor:

DAIICHI SANKYO Co., Ltd.

Luncheon Seminar 22

Closing in on the pathophysiology of cardiorenal syndrome
～Impact of Indoxyl sulfate in cardio-renal interaction～

Co-sponsor:

Mitsubishi Tanabe Pharma Corporation

Luncheon Seminar 23

Changes in Pulmonary Hypertension Medical Care
～Yesterday, Today, and Tomorrow～

Co-sponsor:

Mochida Pharmaceutical Co., Ltd.

Luncheon Seminar 24

Clinical Outcome Endoscopically Guided Ablation System in Japan and Clinical Update of Europe

Co-sponsor:

Japan Lifeline Co., Ltd.

Luncheon Seminar 25

The importance of cardiovascular and respiratory disease control in the elderly

Co-sponsor:

Pfizer Japan Inc.

Luncheon Seminar 26

NOACs in atrial fibrillation: From Clinical Trials to Real World practice

Co-sponsor:

Bristol-Myers Squibb / Pfizer Japan Inc.

Luncheon Seminar 27

Clinical Update on Pharmacotherapy of Atrial Fibrillation - Based on New Guidelines for Drug Treatment of Arrhythmias -

Co-sponsor:

TOA EIYO LTD.

Luncheon Seminar 28

Positioning of SGLT2 inhibitors in Type 2 Diabetes Treatment

Co-sponsor:

ONO PHARMACEUTICAL CO., LTD. / AstraZeneca K.K.

Luncheon Seminar 29

How to select the best SAVR valves by Heart Team

Co-sponsor:

Abbott Medical Japan LLC

Luncheon Seminar 30

New Horizons of Residual Cardiovascular Risk

Co-sponsor:

Kowa Company, Ltd.

Luncheon Seminar 31

The essence of the latest CRT guideline

Co-sponsor:

Medtronic Japan Co.,Ltd.

Luncheon Seminar 32

Let's Think About siRNA

Co-sponsor:

Alnylam Japan K.K.

Luncheon Seminar 33

Comprehensive management of dyslipidemia

Co-sponsor:

Mochida Pharmaceutical Co., Ltd.

Luncheon Seminar 34

ATTR amyloidosis. Where are these patients?

Co-sponsor:

Pfizer Japan Inc.

Luncheon Seminar 35

Impella Heart Pump
Hemodynamic Support and Acute Cardiac Unloading for HEART RECOVERY

Co-sponsor:

Abiomed Japan K.K.

Luncheon Seminar 36

Secondary stroke prevention with PFO closure -For successful introduction to Japan learning from global experience-

Co-sponsor:

Abbott Medical Japan LLC

Luncheon Seminar 37

Know diabetic heart disease by the “CVOTs” -Worth revisiting glucagon-

Co-sponsor:

MSD K.K.

Luncheon Seminar 38

Potentiality of diagnostic imaging in clinical practice for patients with Fabry disease

Co-sponsor:

JCR Pharmaceuticals Co., Ltd.

Luncheon Seminar 39

How Can We Help Constipation Patients Have Natural Bowel Movement?

Co-sponsor:

Mylan EPD G.K.

Luncheon Seminar 40

IMPACT of WATCHMAN : for Your Patients, for Your Strategy, for the World

Co-sponsor:

Boston Scientific Japan K.K.

Luncheon Seminar 41

Do you use metformin in diabetes patients with a high risk for heart failure?

Co-sponsor:

Takeda Pharmaceutical Company Limited

Luncheon Seminar 42

All You Need to Know about the Guideline Update ～Treatment of Aortic Stenosis for Today～

Co-sponsor:

Edwards Lifesciences Ltd.

Luncheon Seminar 43

2019 JCS, AHA/ACC, and ESC/EAS Guidelines for the management of dyslipidaemias: New Topic Llipid Modification to Reduce Cardiovascular Events

Co-sponsor:

MSD K.K. / Bayer Yakuhin, Ltd.

Luncheon Seminar 44

Investigate the cause of cardiopathy -Fabry disease-

Co-sponsor:

Sumitomo Dainippon Pharma Co., Ltd.

Luncheon Seminar 45

A new enlightenment of diagnostic ultrasound system

Co-sponsor:

CANON MEDICAL SYSTEMS CORPORATION

Luncheon Seminar 46

Anticoagulant Therapy for VTE: The New Paradigm of Risk-Benefit

Co-sponsor:

Bristol-Myers Squibb / Pfizer Japan Inc.

Luncheon Seminar 47

Anticoagulant Therapy for Atrial Fibrillation Patients with High Risk: from Prospective trials in Japanese

Co-sponsor:

Bayer Yakuhin, Ltd.

Luncheon Seminar 48

Clinical significance of intensive lipid-lowering therapy and my expectation for PCSK9 inhibitor

Co-sponsor:

Astellas Pharma Inc. / Amgen Astellas BioPharma K.K.

Luncheon Seminar 49

Strategy for Heart Failure with Atrial Fibrillation

Co-sponsor:

Johnson and Johnson K.K. Medical Company

Luncheon Seminar 50

Precision Medicine of Coronary Artery Diseases

Co-sponsor:

Nippon Boehringer Ingelheim Co., Ltd.

Luncheon Seminar 51

GLP-1 receptor agonists for the treatment of T2DM and management of CVD

Co-sponsor:

Novo Nordisk Pharma Ltd. CMR development Div. Medical Affairs Department

Luncheon Seminar 52

Challenging Issues of TAVI   - PCI after TAVI, Conduction Defects, and Durability –

Co-sponsor:

Medtronic Japan Co.,Ltd.

Luncheon Seminar 53

New treatment of heart failure by Kampo medicine
～Tips on using Risuizai～

Co-sponsor:

Tsumura＆Co.

Luncheon Seminar 54

Gastrointestinal disorders that cardiologists should be aware of　~ Constipation is boring but important ~

Co-sponsor:

Astellas Pharma Inc.

Luncheon Seminar 55

PAH treatment strategy to improve long-term survival

Co-sponsor:

Actelion Pharmaceuticals Japan Ltd. / NIPPON SHINYAKU CO., LTD.

Luncheon Seminar 56

MitraClip^® from the latest evidence  – 100,000 patients treated with MitraClip^® -

Co-sponsor:

Abbott Vascular Japan Co., Ltd.

Luncheon Seminar 57

Treatment of type 2 diabetes from the viewpoint of cardiologist

Co-sponsor:

Mitsubishi Tanabe Pharma Corporation / DAIICHI SANKYO COMPANY, LIMITED

Luncheon Seminar 58

Updated aggressive treatment for PAH 2020

Co-sponsor:

Bayer Yakuhin, Ltd.

Luncheon Seminar 59

Diabetes Treatment from the point of view of a cardiologist
～ Saving insulin secretion with metformin ～

Co-sponsor:

Sumitomo Dainippon Pharma Co., Ltd.

Luncheon Seminar 60

The renovation of the long time ECG monitoring strategy

Co-sponsor:

Fukuda Denshi Co., Ltd.

Luncheon Seminar 61

Hypertensive phenotype (Isolated diastolic hypertension): Clinical practice on the basis of pathophysiology and The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2019)

Co-sponsor:

Takeda Pharmaceutical Company Limited

Luncheon Seminar 62

Treatment Strategies for Sleep Disorders Breathing in Heart Failure ～thinking by heart failure stage～

Co-sponsor:

TEIJIN PHARMA LIMITED / ResMed Limited

Luncheon Seminar 63

Ultrastructural Endothelial Injury and Antithrombin

Co-sponsor:

Japan Blood Products Organization

Luncheon Seminar 64

A Practical Approach to Diagnosis of Fabry Disease and　Mucopolysaccharidosis in Cardiovascular Medicine

Co-sponsor:

Sanofi K.K.

Luncheon Seminar 65

Utilization of imaging modality in diagnosis of Chronic Coronary Syndrome(CCS)

Co-sponsor:

Japanese Society of Nuclear Cardiology / FUJIFILM Toyama Chemical Co., LTD.

Luncheon Seminar 66

Cardiovascular disease at the time of disaster：Changes over time of disaster-related diseases and necessary tests
-Examining the heart with biomarkers-

Co-sponsor:

Ortho Clinical Diagnostics Japan

Luncheon Seminar 67

Prognostic Relevance of Heart Rate in Heart Failure

Co-sponsor:

ONO PHARMACEUTICAL CO., LTD.

Luncheon Seminar 68

SGLT2i and Cardiorenal Protection for T2DM: A mechanistic and clinical perspective

Co-sponsor:

Nippon Boehringer Ingelheim Co., Ltd. / Eli Lilly Japan K.K.

Luncheon Seminar 69

Current status of combination therapy and future treatment strategies in Japanese patients with pulmonary arterial hypertension

Co-sponsor:

GlaxoSmithKline K.K.

Luncheon Seminar 70

Appropriate screening, precise diagnosis and novel therapeutic intervention for cardiac amyloidosis

Co-sponsor:

Pfizer Japan Inc.

Luncheon Seminar 71

How to implement results from evidence at DOACs ; Cardioversion, Catheter ablation and AF-PCI in clinical routine?

Co-sponsor:

DAIICHI SANKYO CO., LTD.

Morning Seminar

Morning Seminar 7

What do you think about diagnosis for stable coronary disease?
- Post ISCHEMIA Trail -

Co-sponsor:

HeartFlow Japan G.K.

Morning Seminar 9

Update on Large vessel vasculitis: pathophysiology, diagnosis and treatment

Co-sponsor:

CHUGAI PHARMACEUTICAL CO., LTD.

Morning Seminar 41

Benefits of Lowering LDL-C with PCSK9i to Reduce Cardiovascular Event

Co-sponsor:

Amgen Asia Holding Limited

Morning Seminar 28

Current diagnosis and treatment strategy of pulmonary hypertension

Co-sponsor:

GlaxoSmithKline K.K.

Morning Seminar 40

Management of heart failure and integrated healthcare networks - Facing the heart failure pandemic-

Co-sponsor:

Amgen Astellas BioPharma K.K.

Morning Seminar 42

Antithrombotic therapy in patients with AF and PCI or ACS

Co-sponsor:

Bayer Yakuhin, Ltd.

Fireside Seminar

Fireside Seminar 1

【1】 18:40-19:30　Precision Medicine for Future Cardiovascular Pharmacotherapy
【2】 19:30-20:40　Tobacco Control in Western-Pacific Region 2020-2030

Co-organizer:

Japan Cardiovascular Association (JCVA)

Fireside Seminar 2

LAA Management for stroke prevention

Co-sponsor:

Century Medical, Inc.

Fireside Seminar 4

Anticoagulant therapy -Visiting old, Learn new-

Co-sponsor:

Nippon Boehringer Ingelheim Co., Ltd.

Fireside Seminar 6

Current trend of antiplatelet therapy in US and Japan

Co-sponsor:

Terumo Corporation

Fireside Seminar 7

The role of MRA in the treatment of chronic heart failure

Co-sponsor:

Pfizer Japan Inc.

Fireside Seminar 8

Sudden cardiac death management for ischemic and nonischemic heart failure by EPs

Co-sponsor:

Asahi Kasei ZOLL Medical Corporation

Fireside Seminar 9

Cardio Pulmonary Coupling (CPC) - New Technology of Sleep Quality Measurement

Co-sponsor:

MAGnet Ltd.

Fireside Seminar 10

Progress in the Research on Coronary Spasm -From Elucidation of Molecular Mechanism and Pathophysiology to International Collaboration Study

Co-sponsor:

Japanese Coronary Spasm Association

Fireside Seminar 11

Current status and issues of the lipid-lowering therapy in acute coronary syndromes

Co-sponsor:

Sanofi K.K.

Fireside Seminar 12

Antithrombotic Therapy Update ～Interpretation of new guidelines～

Co-sponsor:

DAIICHI SANKYO Co., Ltd.

Fireside Seminar 13

Responsible for global cardiovascular interventions - Evolution of catheter treatment, From DES to Watchman -

Co-sponsor:

Boston Scientific Japan K.K.

Fireside Seminar 16

Change Practice!! For Japanese Patients with Coronary Artery Disease

Co-sponsor:

Abbott Vascular Japan Co., Ltd.

Coffee Break Seminar

Coffee Break Seminar 1

Depth of the FROZEN -pursuing further possibilities of Cryoablation-

Co-sponsor:

Medtronic Japan Co., Ltd.

Coffee Break Seminar 2

TAV in SAV: A Necessary Part of TAVI’s Future?

Co-sponsor:

Medtronic Japan Co., Ltd.